



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Tubuloreticular inclusions in COVID-19–related collapsing glomerulopathy

François Gaillard^{1,8}, Sophie Ismael^{2,3,8}, Aurélie Sannier⁴, Hassan Tahrini^{2,3}, Thomas Volpe^{2,3}, Clarisse Greze¹, Marie Christine Verpont^{5,6}, Ilyass Zouhry⁴, Christophe Rioux^{2,3}, François-Xavier Lescure^{2,3}, David Buob^{7,9} and Eric Daugas^{1,9}

¹Department of Nephrology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université de Paris, Centre de recherche sur l'inflammation, INSERM UMR1149, CNRS EL8252, Laboratoire d'Excellence Inflammex, Université de Paris, Paris, France; ²Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; ³Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France; ⁴Service d'Anatomie et Cytologie Pathologiques, Assistance Publique – hôpitaux de Paris, hôpital Bichat, Université de Paris, INSERM UMR1148, F-75018, Paris, France; ⁵Institut National de la Santé Et de la Recherche Médicale, UMRS 1155, plateforme d'imagerie et de cytométrie, Hôpital Tenon, Paris, France; ⁶Sorbonne Université, UMRS 1155, F-75020, Paris, France; and ⁷Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Service d'Anatomie et Cytologie Pathologiques, INSERM, UMRS 1155, Hôpital Tenon, Paris, France

Correspondence: François Gaillard, Université de Paris, Centre de recherche sur l'inflammation, INSERM, Université de Paris, Department of Nephrology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Laboratoire d'Excellence Inflammex, UMR1149, CNRS EL8252, 46, rue Henri Huchard, Paris 75018, Île-de-France, France. E-mail: gaillard.f@protonmail.com

⁸These authors contributed equally to this work.

⁹These authors contributed equally to this work.

Kidney International (2020) **98**, 241; <https://doi.org/10.1016/j.kint.2020.04.022>

Copyright © 2020, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

A 79-year-old man of African ancestry, with a history of hemorrhagic stroke, monoclonal gammopathy of unknown significance, and stage 3 chronic kidney disease due to hypertension, was admitted to Bichat Hospital on day 1 after the first symptom of coronavirus disease 2019 (COVID-19) (fever). Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction was positive on nasal swab. At admission, urinary dipstick was normal and plasma creatinine was 224 $\mu\text{mol/l}$. On day 4 plasma albumin was at 29 g/l and proteinuria was 11.4 g per gram of urinary creatinine (80% of albumin). HIV serology was negative, and no other virus was found (hepatitis B virus, hepatitis C virus, cytomegalovirus, Epstein-Barr virus). Autoimmunity markers including antinuclear antibodies, antineutrophil cytoplasm antibodies, and rheumatoid factor were negative. Transcutaneous renal biopsy was performed on day 5. On day 8 the patient was anuric and required hemodialysis and received the first plasma exchange. A treatment with ritonavir/lopinavir and dexamethasone (55 mg in 6 days) was given. He received a total of 7 plasma exchanges. The patient was still under intermittent hemodialysis, and nephrotic syndrome was unchanged 21 days after the first symptoms of COVID-19.

Renal histology showed a collapsing glomerulopathy with acute tubular necrosis (Figure 1). Electron microscopy revealed severe podocyte changes including diffuse foot process effacement and marked cytoplasmic vacuolization. No characteristic




Figure 1 | (a) Periodic acid-Schiff staining showing the collapsing of glomerular tuft, podocyte vacuolization, and acute tubular necrosis. Bar = 0.1 mm. (b) Tubuloreticular inclusion (arrow) in glomerular endothelial cell. Asterisks indicate glomerular basement membrane (white) and capillary lumen (black). Bar = 500 nm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.

viral particles were seen. Furthermore, there were diffuse signs of endothelial injury, in both peritubular and glomerular capillaries, including swelling of endothelial cells. Interestingly, glomerular endothelial cells contained numerous tubuloreticular inclusions (also known as “interferon footprints”) as shown on Figure 1b. Tubuloreticular inclusions can be observed during lupus nephritis, interferon treatment, and various viral infections, especially HIV. These findings suggest a systemic response to severe acute respiratory syndrome coronavirus 2 with enhanced type 1 interferon expression, which may be responsible for the glomerular and endothelial lesions.